JPWO2020092654A5

JPWO2020092654A5 -

Download PDF

Info

Publication number: JPWO2020092654A5
Authority: JP; Japan
Prior art keywords: antibody; amino acid; seq; optionally substituted; antigen
Prior art date: 2022-11-07
Legal status : Pending

Application number

JP2021521765A

Other languages

English (en)

Japanese (ja)

Other versions

JP2022512778A (ja

Publication date

2022-11-07

2019-10-30 Application filed filed Critical

2019-10-30 Priority claimed from PCT/US2019/058971 external-priority patent/WO2020092654A1/fr

2022-02-07 Publication of JP2022512778A publication Critical patent/JP2022512778A/ja

2022-11-07 Publication of JPWO2020092654A5 publication Critical patent/JPWO2020092654A5/ja

Status Pending legal-status Critical Current

Links

102000004965 antibodies Human genes 0.000 claims description 610
108090001123 antibodies Proteins 0.000 claims description 610
125000005647 linker group Chemical group 0.000 claims description 261
230000027455 binding Effects 0.000 claims description 236
239000000427 antigen Substances 0.000 claims description 202
108091007172 antigens Proteins 0.000 claims description 201
102000038129 antigens Human genes 0.000 claims description 201
210000004027 cells Anatomy 0.000 claims description 171
125000003275 alpha amino acid group Chemical group 0.000 claims description 150
102100005499 PTPRC Human genes 0.000 claims description 124
101700059076 PTPRC Proteins 0.000 claims description 124
239000000611 antibody drug conjugate Substances 0.000 claims description 115
108091008116 antibody drug conjugates Proteins 0.000 claims description 115
210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims description 111
235000001014 amino acid Nutrition 0.000 claims description 93
231100000599 cytotoxic agent Toxicity 0.000 claims description 64
239000002619 cytotoxin Substances 0.000 claims description 64
230000036961 partial Effects 0.000 claims description 62
125000001424 substituent group Chemical group 0.000 claims description 57
108010004143 Alpha-amanitin Proteins 0.000 claims description 55
101700027111 3SA0 Proteins 0.000 claims description 54
150000001413 amino acids Chemical class 0.000 claims description 54
101700067609 ctx Proteins 0.000 claims description 54
231100000729 Amatoxin Toxicity 0.000 claims description 46
239000000203 mixture Substances 0.000 claims description 41
239000000126 substance Substances 0.000 claims description 39
238000006467 substitution reaction Methods 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 34
108010014709 amatoxin Proteins 0.000 claims description 33
108010016626 Dipeptides Proteins 0.000 claims description 32
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 28
201000011510 cancer Diseases 0.000 claims description 25
241000282567 Macaca fascicularis Species 0.000 claims description 23
230000002401 inhibitory effect Effects 0.000 claims description 23
239000003112 inhibitor Substances 0.000 claims description 20
125000001072 heteroaryl group Chemical group 0.000 claims description 19
210000002865 immune cell Anatomy 0.000 claims description 17
206010003816 Autoimmune disease Diseases 0.000 claims description 15
102000004851 Immunoglobulin G Human genes 0.000 claims description 15
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 15
206010024324 Leukaemias Diseases 0.000 claims description 14
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 13
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 13
125000004430 oxygen atoms Chemical group O* 0.000 claims description 13
241000658540 Ora Species 0.000 claims description 12
231100000765 Toxin Toxicity 0.000 claims description 12
108010044540 auristatin Proteins 0.000 claims description 12
239000003053 toxin Substances 0.000 claims description 12
241000282693 Cercopithecidae Species 0.000 claims description 11
241000282560 Macaca mulatta Species 0.000 claims description 11
238000005859 coupling reaction Methods 0.000 claims description 11
125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 10
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 10
125000004419 alkynylene group Chemical group 0.000 claims description 10
125000004474 heteroalkylene group Chemical group 0.000 claims description 10
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 9
125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 8
125000004450 alkenylene group Chemical group 0.000 claims description 8
230000000735 allogeneic Effects 0.000 claims description 8
108091006028 chimera Proteins 0.000 claims description 8
125000006588 heterocycloalkylene group Chemical group 0.000 claims description 8
125000000732 arylene group Chemical group 0.000 claims description 7
201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims description 7
239000000539 dimer Substances 0.000 claims description 7
125000005549 heteroarylene group Chemical group 0.000 claims description 7
208000008466 Metabolic Disease Diseases 0.000 claims description 6
125000005717 substituted cycloalkylene group Chemical group 0.000 claims description 6
CIORWBWIBBPXCG-JZTFPUPKSA-N Amanitin Chemical group O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims description 5
201000002393 blood protein disease Diseases 0.000 claims description 5
239000007943 implant Substances 0.000 claims description 5
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
VQNATVDKACXKTF-XELLLNAOSA-N Duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 4
208000002491 Severe Combined Immunodeficiency Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
125000003107 substituted aryl group Chemical group 0.000 claims description 4
MFRNYXJJRJQHNW-DEMKXPNLSA-N (2S)-2-[[(2R,3R)-3-methoxy-3-[(2S)-1-[(3R,4S,5S)-3-methoxy-5-methyl-4-[methyl-[(2S)-3-methyl-2-[[(2S)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 3
206010061590 Blood disease Diseases 0.000 claims description 3
DASWEROEPLKSEI-UIJRFTGLSA-N Monomethyl auristatin E Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 DASWEROEPLKSEI-UIJRFTGLSA-N 0.000 claims description 3
201000002138 hematopoietic system disease Diseases 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
-1 de bouganine Proteins 0.000 description 108
230000035772 mutation Effects 0.000 description 89
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 87
239000000562 conjugate Substances 0.000 description 65
239000003814 drug Substances 0.000 description 62
229940079593 drugs Drugs 0.000 description 45
201000010099 disease Diseases 0.000 description 41
PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 39
238000000034 method Methods 0.000 description 39
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 38
108010047041 Complementarity Determining Regions Proteins 0.000 description 29
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 27
238000006243 chemical reaction Methods 0.000 description 25
150000001875 compounds Chemical class 0.000 description 25
PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 23
150000002019 disulfides Chemical class 0.000 description 23
238000002560 therapeutic procedure Methods 0.000 description 23
102000018358 Immunoglobulins Human genes 0.000 description 22
108060003951 Immunoglobulins Proteins 0.000 description 22
125000003118 aryl group Chemical group 0.000 description 22
238000004166 bioassay Methods 0.000 description 22
125000004432 carbon atoms Chemical group C* 0.000 description 22
230000001472 cytotoxic Effects 0.000 description 21
230000004048 modification Effects 0.000 description 21
238000006011 modification reaction Methods 0.000 description 21
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 21
230000002829 reduced Effects 0.000 description 21
210000001772 Blood Platelets Anatomy 0.000 description 20
231100000433 cytotoxic Toxicity 0.000 description 20
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 19
235000018417 cysteine Nutrition 0.000 description 18
ALBYIUDWACNRRB-UHFFFAOYSA-N hexanamide Chemical compound CCCCCC(N)=O ALBYIUDWACNRRB-UHFFFAOYSA-N 0.000 description 18
238000000338 in vitro Methods 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 18
210000000138 Mast Cells Anatomy 0.000 description 17
210000001744 T-Lymphocytes Anatomy 0.000 description 17
125000000539 amino acid group Chemical group 0.000 description 17
125000005842 heteroatoms Chemical group 0.000 description 17
150000007523 nucleic acids Chemical class 0.000 description 17
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 17
210000003743 Erythrocytes Anatomy 0.000 description 16
230000003750 conditioning Effects 0.000 description 16
230000001268 conjugating Effects 0.000 description 16
230000000875 corresponding Effects 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
229920001184 polypeptide Polymers 0.000 description 16
STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 15
108010029485 Protein Isoforms Proteins 0.000 description 15
102000001708 Protein Isoforms Human genes 0.000 description 15
150000003573 thiols Chemical class 0.000 description 15
230000003394 haemopoietic Effects 0.000 description 14
238000002054 transplantation Methods 0.000 description 14
230000036499 Half live Effects 0.000 description 13
102000028664 Microtubules Human genes 0.000 description 13
108091022031 Microtubules Proteins 0.000 description 13
210000004688 Microtubules Anatomy 0.000 description 13
206010039073 Rheumatoid arthritis Diseases 0.000 description 13
239000004007 alpha amanitin Substances 0.000 description 13
239000011230 binding agent Substances 0.000 description 13
229910052799 carbon Inorganic materials 0.000 description 13
239000003153 chemical reaction reagent Substances 0.000 description 13
125000003396 thiol group Chemical group [H]S* 0.000 description 13
CIORWBWIBBPXCG-SXZCQOKQSA-N α-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 13
XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
230000000269 nucleophilic Effects 0.000 description 12
210000001519 tissues Anatomy 0.000 description 12
AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
230000021615 conjugation Effects 0.000 description 11
229920003013 deoxyribonucleic acid Polymers 0.000 description 11
210000000130 stem cell Anatomy 0.000 description 11
229910052717 sulfur Inorganic materials 0.000 description 11
150000003568 thioethers Chemical class 0.000 description 11
108020003112 toxins Proteins 0.000 description 11
108060001251 CD34 Proteins 0.000 description 10
102100016492 CD34 Human genes 0.000 description 10
229960004679 Doxorubicin Drugs 0.000 description 10
210000002540 Macrophages Anatomy 0.000 description 10
HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 description 10
230000001413 cellular Effects 0.000 description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
230000004083 survival Effects 0.000 description 10
QCZXQEYEVLCQHL-MIBTZWEZSA-N Amanin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=CC=C2N1 QCZXQEYEVLCQHL-MIBTZWEZSA-N 0.000 description 9
BOHCOUQZNDPURZ-MIBTZWEZSA-N Amaninamide Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=CC=C2N1 BOHCOUQZNDPURZ-MIBTZWEZSA-N 0.000 description 9
210000003719 B-Lymphocytes Anatomy 0.000 description 9
101800001350 Beta-amanitin Proteins 0.000 description 9
241000282412 Homo Species 0.000 description 9
210000000822 Killer Cells, Natural Anatomy 0.000 description 9
210000004698 Lymphocytes Anatomy 0.000 description 9
239000004472 Lysine Substances 0.000 description 9
125000003342 alkenyl group Chemical group 0.000 description 9
108010004258 amaninamide Proteins 0.000 description 9
125000003277 amino group Chemical group 0.000 description 9
239000004080 beta amanitin Substances 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
125000004051 hexyl group Chemical compound [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 9
238000002703 mutagenesis Methods 0.000 description 9
231100000350 mutagenesis Toxicity 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
238000011160 research Methods 0.000 description 9
230000001225 therapeutic Effects 0.000 description 9
IEQCUEXVAPAFMQ-JAXJKTSHSA-N β-Amanitin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 IEQCUEXVAPAFMQ-JAXJKTSHSA-N 0.000 description 9
WVHGJJRMKGDTEC-ZUROAWGWSA-N γ-Amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 WVHGJJRMKGDTEC-ZUROAWGWSA-N 0.000 description 9
OFILNAORONITPV-ZUROAWGWSA-N ε-Amanitin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 OFILNAORONITPV-ZUROAWGWSA-N 0.000 description 9
QQLVIKWYAVVKKF-XYDKGUIVSA-N Amanullin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 QQLVIKWYAVVKKF-XYDKGUIVSA-N 0.000 description 8
HFENEIQMWRYNGK-XYDKGUIVSA-N Amanullinic acid Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 HFENEIQMWRYNGK-XYDKGUIVSA-N 0.000 description 8
210000004369 Blood Anatomy 0.000 description 8
210000004443 Dendritic Cells Anatomy 0.000 description 8
108010087819 Fc receptors Proteins 0.000 description 8
102000009109 Fc receptors Human genes 0.000 description 8
108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 8
102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 8
210000000440 Neutrophils Anatomy 0.000 description 8
CTYHFRWAIRSHQT-YRDOMICZSA-N Proamanullin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CTYHFRWAIRSHQT-YRDOMICZSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
239000008280 blood Substances 0.000 description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
230000001404 mediated Effects 0.000 description 8
NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
238000002965 ELISA Methods 0.000 description 7
210000003979 Eosinophils Anatomy 0.000 description 7
210000003714 Granulocytes Anatomy 0.000 description 7
108010073807 IgG Receptors Proteins 0.000 description 7
102000009490 IgG Receptors Human genes 0.000 description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 7
125000006193 alkinyl group Chemical group 0.000 description 7
125000003710 aryl alkyl group Chemical group 0.000 description 7
238000003776 cleavage reaction Methods 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
230000003013 cytotoxicity Effects 0.000 description 7
231100000135 cytotoxicity Toxicity 0.000 description 7
230000001419 dependent Effects 0.000 description 7
125000000524 functional group Chemical group 0.000 description 7
125000000623 heterocyclic group Chemical group 0.000 description 7
229910052739 hydrogen Inorganic materials 0.000 description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
230000003993 interaction Effects 0.000 description 7
230000003834 intracellular Effects 0.000 description 7
229910052760 oxygen Inorganic materials 0.000 description 7
238000000159 protein binding assay Methods 0.000 description 7
210000000601 Blood Cells Anatomy 0.000 description 6
150000001299 aldehydes Chemical class 0.000 description 6
230000001363 autoimmune Effects 0.000 description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
230000002860 competitive Effects 0.000 description 6
230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
230000002708 enhancing Effects 0.000 description 6
125000004404 heteroalkyl group Chemical group 0.000 description 6
125000004435 hydrogen atoms Chemical group [H]* 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
241000894007 species Species 0.000 description 6
125000000547 substituted alkyl group Chemical group 0.000 description 6
125000004426 substituted alkynyl group Chemical group 0.000 description 6
201000010874 syndrome Diseases 0.000 description 6
150000003923 2,5-pyrrolediones Chemical compound 0.000 description 5
VTRGCUISDBTZIB-UHFFFAOYSA-N 2-aminooxyacetamide Chemical compound NOCC(N)=O VTRGCUISDBTZIB-UHFFFAOYSA-N 0.000 description 5
206010000880 Acute myeloid leukaemia Diseases 0.000 description 5
AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 5
101710044656 FCGR3A Proteins 0.000 description 5
102100015541 FCGR3A Human genes 0.000 description 5
101710044657 FCGR3B Proteins 0.000 description 5
230000035693 Fab Effects 0.000 description 5
239000004471 Glycine Substances 0.000 description 5
208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 5
102000035443 Peptidases Human genes 0.000 description 5
108091005771 Peptidases Proteins 0.000 description 5
FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 5
241000700159 Rattus Species 0.000 description 5
239000002253 acid Substances 0.000 description 5
238000007792 addition Methods 0.000 description 5
125000000304 alkynyl group Chemical group 0.000 description 5
125000002619 bicyclic group Chemical group 0.000 description 5
238000002838 bio layer interferometry Methods 0.000 description 5
239000000306 component Substances 0.000 description 5
125000000392 cycloalkenyl group Chemical group 0.000 description 5
230000002950 deficient Effects 0.000 description 5
238000005755 formation reaction Methods 0.000 description 5
210000004602 germ cell Anatomy 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000001965 increased Effects 0.000 description 5
210000003292 kidney cell Anatomy 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
238000002823 phage display Methods 0.000 description 5
229910052698 phosphorus Inorganic materials 0.000 description 5
OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
230000011664 signaling Effects 0.000 description 5
VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 4
JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 4
210000001185 Bone Marrow Anatomy 0.000 description 4
206010053138 Congenital aplastic anaemia Diseases 0.000 description 4
229960001904 EPIRUBICIN Drugs 0.000 description 4
102100015544 FCGR2C Human genes 0.000 description 4
229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
229950001474 Maitansine Drugs 0.000 description 4
210000003593 Megakaryocytes Anatomy 0.000 description 4
210000000274 Microglia Anatomy 0.000 description 4
210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 4
210000002381 Plasma Anatomy 0.000 description 4
239000004365 Protease Substances 0.000 description 4
210000003324 RBC Anatomy 0.000 description 4
108010084592 Saporins Proteins 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
230000002378 acidificating Effects 0.000 description 4
125000002947 alkylene group Chemical group 0.000 description 4
125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 4
239000002246 antineoplastic agent Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000003008 brain-resident macrophage Anatomy 0.000 description 4
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
XZMCDFZZKTWFGF-UHFFFAOYSA-N carbodiimide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 4
239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
230000011132 hemopoiesis Effects 0.000 description 4
125000004446 heteroarylalkyl group Chemical group 0.000 description 4
125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 4
150000007857 hydrazones Chemical class 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
229960004768 irinotecan Drugs 0.000 description 4
230000002147 killing Effects 0.000 description 4
210000004962 mammalian cells Anatomy 0.000 description 4
125000002950 monocyclic group Chemical group 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
229920000023 polynucleotide Polymers 0.000 description 4
239000002157 polynucleotide Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 4
RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
238000003860 storage Methods 0.000 description 4
125000004434 sulfur atoms Chemical group 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 description 3
VQZYZXLBKBUOHE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)butanoate Chemical compound C=1C=CC=NC=1SSC(C)CC(=O)ON1C(=O)CCC1=O VQZYZXLBKBUOHE-UHFFFAOYSA-N 0.000 description 3
FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 3
210000000612 Antigen-Presenting Cells Anatomy 0.000 description 3
229960005261 Aspartic Acid Drugs 0.000 description 3
102100013077 CD4 Human genes 0.000 description 3
101700022938 CD4 Proteins 0.000 description 3
241000699802 Cricetulus griseus Species 0.000 description 3
229960000975 Daunorubicin Drugs 0.000 description 3
108010053187 Diphtheria Toxin Proteins 0.000 description 3
102000016607 Diphtheria Toxin Human genes 0.000 description 3
241000206602 Eukaryota Species 0.000 description 3
102100008658 FN1 Human genes 0.000 description 3
108010067306 Fibronectins Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
102100019441 ITGAM Human genes 0.000 description 3
101710006572 ITGAM Proteins 0.000 description 3
229960000908 Idarubicin Drugs 0.000 description 3
210000000987 Immune System Anatomy 0.000 description 3
206010022114 Injury Diseases 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 3
210000002997 Osteoclasts Anatomy 0.000 description 3
206010025310 Other lymphomas Diseases 0.000 description 3
210000001672 Ovary Anatomy 0.000 description 3
229960005190 Phenylalanine Drugs 0.000 description 3
206010035226 Plasma cell myeloma Diseases 0.000 description 3
108010077397 Pseudomonas aeruginosa toxA protein Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
206010039710 Scleroderma Diseases 0.000 description 3
210000002356 Skeleton Anatomy 0.000 description 3
102100008333 THY1 Human genes 0.000 description 3
101700026084 THY1 Proteins 0.000 description 3
JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 3
125000002252 acyl group Chemical group 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
235000003704 aspartic acid Nutrition 0.000 description 3
125000004429 atoms Chemical group 0.000 description 3
IVRMZWNICZWHMI-UHFFFAOYSA-N azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 3
230000001580 bacterial Effects 0.000 description 3
239000011324 bead Substances 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
230000003115 biocidal Effects 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000004663 cell proliferation Effects 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
230000003247 decreasing Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 3
230000037320 fibronectin Effects 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
125000001188 haloalkyl group Chemical group 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
239000003446 ligand Substances 0.000 description 3
238000011068 load Methods 0.000 description 3
230000002934 lysing Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000002609 media Substances 0.000 description 3
230000000051 modifying Effects 0.000 description 3
102000005614 monoclonal antibodies Human genes 0.000 description 3
108010045030 monoclonal antibodies Proteins 0.000 description 3
201000000050 myeloid neoplasm Diseases 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000002148 osteoclast Effects 0.000 description 3
230000001575 pathological Effects 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
238000009168 stem cell therapy Methods 0.000 description 3
238000009580 stem-cell therapy Methods 0.000 description 3
230000002194 synthesizing Effects 0.000 description 3
239000004474 valine Substances 0.000 description 3
235000014393 valine Nutrition 0.000 description 3
108010073969 valyllysine Proteins 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
FLCQLSRLQIPNLM-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-acetylsulfanylacetate Chemical compound CC(=O)SCC(=O)ON1C(=O)CCC1=O FLCQLSRLQIPNLM-UHFFFAOYSA-N 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
125000006686 (C1-C24) alkyl group Chemical group 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
MOCVYVBNJQIVOV-TVQRCGJNSA-N 5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-2-methylchromen-4-one Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
OVMSOCFBDVBLFW-VHLOTGQHSA-N 5β,20-epoxy-1,7β,13α-trihydroxy-9-oxotax-11-ene-2α,4α,10β-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
208000007502 Anemia Diseases 0.000 description 2
229940064005 Antibiotic throat preparations Drugs 0.000 description 2
229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
229940042052 Antibiotics for systemic use Drugs 0.000 description 2
229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
206010002967 Aplastic anaemia Diseases 0.000 description 2
HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
DNSISZSEWVHGLH-UHFFFAOYSA-N Butyramide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
101700034624 CASP3 Proteins 0.000 description 2
102100003814 CASP3 Human genes 0.000 description 2
229920002574 CR-39 Polymers 0.000 description 2
102100006400 CSF2 Human genes 0.000 description 2
102100006435 CSF3 Human genes 0.000 description 2
UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 2
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
206010009900 Colitis ulcerative Diseases 0.000 description 2
229920000453 Consensus sequence Polymers 0.000 description 2
206010011401 Crohn's disease Diseases 0.000 description 2
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
206010012601 Diabetes mellitus Diseases 0.000 description 2
201000004449 Diamond-Blackfan anemia Diseases 0.000 description 2
206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 2
229920000665 Exon Polymers 0.000 description 2
101710003440 FCGR1A Proteins 0.000 description 2
102100015540 FCGR1A Human genes 0.000 description 2
101710044640 FCGR2A Proteins 0.000 description 2
101710044641 FCGR2B Proteins 0.000 description 2
101710044642 FCGR2C Proteins 0.000 description 2
201000004939 Fanconi anemia Diseases 0.000 description 2
108010021470 Fc gamma receptor IIC Proteins 0.000 description 2
108091006004 Fc-tagged proteins Proteins 0.000 description 2
101700009480 Fcgr3 Proteins 0.000 description 2
CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
229960002989 Glutamic Acid Drugs 0.000 description 2
229940096919 Glycogen Drugs 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 2
229940093922 Gynecological Antibiotics Drugs 0.000 description 2
208000001284 Hemoglobinopathy Diseases 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
210000004408 Hybridomas Anatomy 0.000 description 2
229960000310 ISOLEUCINE Drugs 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
102100016985 KIT Human genes 0.000 description 2
101710009391 KIT Proteins 0.000 description 2
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline zwitterion Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
241000270322 Lepidosauria Species 0.000 description 2
208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 2
208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 2
210000004185 Liver Anatomy 0.000 description 2
RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 2
229950002654 Lurtotecan Drugs 0.000 description 2
101700052785 Ly6a Proteins 0.000 description 2
206010049646 Lymphohistiocytosis Diseases 0.000 description 2
WKPWGQKGSOKKOO-WLNOZUDTSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-WLNOZUDTSA-N 0.000 description 2
WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical group CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
108020004999 Messenger RNA Proteins 0.000 description 2
229960003539 Mitoguazone Drugs 0.000 description 2
210000001616 Monocytes Anatomy 0.000 description 2
208000002678 Mucopolysaccharidosis Diseases 0.000 description 2
206010028093 Mucopolysaccharidosis Diseases 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
229920001850 Nucleic acid sequence Polymers 0.000 description 2
229920000272 Oligonucleotide Polymers 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229960001592 Paclitaxel Drugs 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
102000002727 Protein Tyrosine Phosphatases Human genes 0.000 description 2
108020000494 Protein Tyrosine Phosphatases Proteins 0.000 description 2
DNXIASIHZYFFRO-UHFFFAOYSA-N Pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
102100018787 RPS19 Human genes 0.000 description 2
101710007829 RPS19 Proteins 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
CGFVUVWMYIHGHS-UHFFFAOYSA-N SAINTOPIN Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 2
101700068919 SCAL1 Proteins 0.000 description 2
239000002262 Schiff base Substances 0.000 description 2
150000004753 Schiff bases Chemical class 0.000 description 2
208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 2
208000007056 Sickle Cell Anemia Diseases 0.000 description 2
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
208000010346 Sphingolipidosis Diseases 0.000 description 2
229950006050 Spiromustine Drugs 0.000 description 2
210000000952 Spleen Anatomy 0.000 description 2
108091008153 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
208000002903 Thalassemia Diseases 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
229960004528 Vincristine Drugs 0.000 description 2
229960002110 Vincristine Sulfate Drugs 0.000 description 2
AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 2
LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
201000005510 acute lymphocytic leukemia Diseases 0.000 description 2
229930013930 alkaloids Natural products 0.000 description 2
150000001345 alkine derivatives Chemical class 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
230000001640 apoptogenic Effects 0.000 description 2
230000002238 attenuated Effects 0.000 description 2
NOWKCMXCCJGMRR-UHFFFAOYSA-N aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000002798 bone marrow cell Anatomy 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
125000003917 carbamoyl group Chemical compound [H]N([H])C(*)=O 0.000 description 2
125000000837 carbohydrate group Chemical group 0.000 description 2
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
239000006143 cell culture media Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
201000006934 chronic myeloid leukemia Diseases 0.000 description 2
229960002173 citrulline Drugs 0.000 description 2
235000013477 citrulline Nutrition 0.000 description 2
229960002436 cladribine Drugs 0.000 description 2
230000000295 complement Effects 0.000 description 2
238000005094 computer simulation Methods 0.000 description 2
230000001143 conditioned Effects 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
229910003460 diamond Inorganic materials 0.000 description 2
239000010432 diamond Substances 0.000 description 2
150000001993 dienes Chemical class 0.000 description 2
238000007876 drug discovery Methods 0.000 description 2
229930013356 epothilones Natural products 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000001747 exhibiting Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037240 fusion proteins Human genes 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
108010062266 glycyl-glycyl-argininal Proteins 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
201000003923 hemoglobinopathy Diseases 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000003308 immunostimulating Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
238000009830 intercalation Methods 0.000 description 2
229940079866 intestinal antibiotics Drugs 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
229920002106 messenger RNA Polymers 0.000 description 2
230000002503 metabolic Effects 0.000 description 2
201000011442 metachromatic leukodystrophy Diseases 0.000 description 2
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
230000002025 microglial Effects 0.000 description 2
MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 2
229960000060 monoclonal antibodies Drugs 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
201000003793 myelodysplastic syndrome Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
229920001542 oligosaccharide Polymers 0.000 description 2
150000002482 oligosaccharides Polymers 0.000 description 2
229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
210000000056 organs Anatomy 0.000 description 2
229960001756 oxaliplatin Drugs 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
230000002093 peripheral Effects 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
239000000546 pharmaceutic aid Substances 0.000 description 2
230000000275 pharmacokinetic Effects 0.000 description 2
238000006303 photolysis reaction Methods 0.000 description 2
230000015843 photosynthesis, light reaction Effects 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000002062 proliferating Effects 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
125000003373 pyrazinyl group Chemical group 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
125000000714 pyrimidinyl group Chemical group 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
239000003638 reducing agent Substances 0.000 description 2
201000001307 sphingolipidosis Diseases 0.000 description 2
JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
230000002459 sustained Effects 0.000 description 2
238000002626 targeted therapy Methods 0.000 description 2
229930003347 taxol Natural products 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
230000002588 toxic Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
201000006704 ulcerative colitis Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
CWGBFIRHYJNILV-UHFFFAOYSA-N (1,4-diphenyl-1,2,4-triazol-4-ium-3-yl)-phenylazanide Chemical group C=1C=CC=CC=1[N-]C1=NN(C=2C=CC=CC=2)C=[N+]1C1=CC=CC=C1 CWGBFIRHYJNILV-UHFFFAOYSA-N 0.000 description 1
GCPUVEMWOWMALU-HZMBPMFUSA-N (1S,3S)-1-hydroxy-8-methoxy-3-methyl-1,2,3,4-tetrahydrobenzo[a]anthracene-7,12-dione Chemical compound C1[C@H](C)C[C@H](O)C2=C1C=CC1=C2C(=O)C(C=CC=C2OC)=C2C1=O GCPUVEMWOWMALU-HZMBPMFUSA-N 0.000 description 1
UFIVODCEJLHUTQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-(1-phenylethyldisulfanyl)-2H-pyridine-1-carboxylate Chemical compound C=1C=CC=CC=1C(C)SSC1C=CC=CN1C(=O)ON1C(=O)CCC1=O UFIVODCEJLHUTQ-UHFFFAOYSA-N 0.000 description 1
FXPSZLHFJDHOMI-DHZHZOJOSA-N (2E)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C/N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-DHZHZOJOSA-N 0.000 description 1
BUSGWUFLNHIBPT-XYBORKQMSA-N (2E,4E,6E)-7-[(1R,5R,6S)-3-[[(2E,4E)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
AKJHMTWEGVYYSE-FXILSDISSA-N (2E,4E,6E,8E)-N-(4-hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide Chemical compound C=1C=C(O)C=CC=1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-FXILSDISSA-N 0.000 description 1
NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
SWTGJCNCBUCXSS-ISUZDFFFSA-N (2R)-3,4-dihydroxy-2-[(4S)-2-phenyl-1,3-dioxolan-4-yl]-2H-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 1
GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
YOZSEGPJAXTSFZ-ZETCQYMHSA-N (2S)-2-amino-3-(5-hydroxypyridin-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
QXRNAOYBCYVZCD-BQBZGAKWSA-N (2S)-6-amino-2-[[(2S)-2-aminopropanoyl]amino]hexanoic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 description 1
UUSZLLQJYRSZIS-GHRWIAHFSA-N (2S)-N-[(2R)-1-[[(3S,6R,8S,12S,13R,16R,17S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4- Chemical compound CN([C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)C(CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-GHRWIAHFSA-N 0.000 description 1
RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
HWMMBHOXHRVLCU-QOUANJGESA-N (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxo-2,4-dihydrobenzo[a]anthracen-9-yl]-2-methyloxan-3-yl]oxy-7-oxohepta-1,3,5-trienyl]-2,5-dimethyl-1,3-dioxolane-2-carboxylic acid Chemical compound C[C@@H]1O[C@](C)(C(O)=O)O[C@H]1\C=C\C=C\C=C\C(=O)OC1[C@@H](C)O[C@@H](C=2C(=C3C(=O)C4=C([C@]5(C(=O)[C@H](O)[C@@](C)(O)C[C@@]5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-QOUANJGESA-N 0.000 description 1
JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
FRYZZSHLYIZKCQ-UHFFFAOYSA-N (4-aminophenyl)methylazanide Chemical group NC1=CC=C(C[NH-])C=C1 FRYZZSHLYIZKCQ-UHFFFAOYSA-N 0.000 description 1
UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
XOZIUKBZLSUILX-GIQCAXHBSA-N (4S,7R,8S,9S,13Z,16S)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 1
GTEXXGIEZVKSLH-YPMHNXCESA-N (4aS,12bR)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
HLAKJNQXUARACO-ZDUSSCGKSA-N (5'R)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
PTBPQBZWBIRISO-IAGVQPJWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(E)-N-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-C-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 PTBPQBZWBIRISO-IAGVQPJWSA-N 0.000 description 1
KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
SLURUCSFDHKXFR-WWMWMSKMSA-N (7S,9S)-7-[[(1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyl-3,4,4a,6,7,9,9a,10a-octahydro-1H-pyrano[1,2][1,3]oxazolo[3,4-b][1,4]oxazin-3-yl]oxy]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=CC=CC(OC)=C2C(=O)C(C(O)=C23)=C1C(O)=C3C[C@@](O)(C(=O)CO)C[C@@H]2O[C@H]1C[C@@H]2N3CCO[C@H](OC)[C@H]3O[C@@H]2[C@H](C)O1 SLURUCSFDHKXFR-WWMWMSKMSA-N 0.000 description 1
VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 description 1
DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
DEPDDPLQZYCHOH-UHFFFAOYSA-N 1H-imidazol-2-amine Chemical class NC1=NC=CN1 DEPDDPLQZYCHOH-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
125000005955 1H-indazolyl group Chemical group 0.000 description 1
KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1H-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1H-imidazole Chemical compound C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(E)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
BMUXBWLKTHLRQC-UHFFFAOYSA-N 2-azanylethanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O BMUXBWLKTHLRQC-UHFFFAOYSA-N 0.000 description 1
HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
108020005345 3' Untranslated Regions Proteins 0.000 description 1
UPGQPDVTCACHAI-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanamide Chemical compound NC(=O)CCSSC1=CC=CC=N1 UPGQPDVTCACHAI-UHFFFAOYSA-N 0.000 description 1
AQIXEPGDORPWBJ-UHFFFAOYSA-N 3-Pentanol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 1
QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 1
WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
HXZRMADPDYFMEB-MLTUFRGDSA-N 3-hydroxy-N-[3-[8-[(E)-6-hydroxy-3,5-dimethylhept-4-enyl]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]propyl]-2-methyl-4-[[2-[3-methyl-6-[(Z)-2-oxopent-3-enyl]oxan-2-yl]acetyl]amino]butanamide Chemical compound O1C(CC(=O)\C=C/C)CCC(C)C1CC(=O)NCC(O)C(C)C(=O)NCCCC1C(C)CCC2(OC(CCC(C)\C=C(/C)C(C)O)CCC2)O1 HXZRMADPDYFMEB-MLTUFRGDSA-N 0.000 description 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1H-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 1
125000005986 4-piperidonyl group Chemical group 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
108020003589 5' Untranslated Regions Proteins 0.000 description 1
APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
BOJKULTULYSRAS-OTESTREVSA-N 5508-58-7 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
TWHSQQYCDVSBRK-UHFFFAOYSA-N 9-[4-(methanesulfonamido)-2-methoxyanilino]-N,5-dimethylacridine-4-carboxamide Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
MSNVESLISHTIRS-UHFFFAOYSA-N 9H-pyrrolo[2,1-c][1,4]benzodiazepine Chemical class N1=C2C=CC=CC2=CN2CC=CC2=C1 MSNVESLISHTIRS-UHFFFAOYSA-N 0.000 description 1
102100001249 ALB Human genes 0.000 description 1
VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
229950004810 ATAMESTANE Drugs 0.000 description 1
241000186361 Actinobacteria <class> Species 0.000 description 1
DPGOLRILOKERAV-AAWJQDODSA-N Adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
102000009914 Adenosine deaminases Human genes 0.000 description 1
108091022188 Adenosine deaminases Proteins 0.000 description 1
229940009456 Adriamycin Drugs 0.000 description 1
OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
241000948470 Amanita phalloides Species 0.000 description 1
229950010949 Ambamustine Drugs 0.000 description 1
JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
229960001097 Amifostine Drugs 0.000 description 1
RAIPHJJURHTUIC-UHFFFAOYSA-N Aminothiazole Chemical group NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
210000004381 Amniotic Fluid Anatomy 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
BOJKULTULYSRAS-QPSYGYIJSA-N Andrographolide Natural products C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 description 1
VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
IOASYARYEYRREA-LQAJYKIKSA-N Aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
229920002395 Aptamer Polymers 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
229960001230 Asparagine Drugs 0.000 description 1
PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
229950006933 Atrimustine Drugs 0.000 description 1
PICZCWCKOLHDOJ-GHTSNYPWSA-N Axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
OXNAATCTZCSVKR-AVGVIDKOSA-N Axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
229950005951 Azasetron Drugs 0.000 description 1
MIXLRUYCYZPSOQ-HXPMCKFVSA-N Azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
108091008154 B cell receptors Proteins 0.000 description 1
102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
210000000649 B-Lymphocyte Subsets Anatomy 0.000 description 1
229950002370 BISNAFIDE Drugs 0.000 description 1
229950006844 BIZELESIN Drugs 0.000 description 1
XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
229950001858 Batimastat Drugs 0.000 description 1
229960001950 Benzethonium Chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
108010071919 Bispecific Antibodies Proteins 0.000 description 1
229940098773 Bovine Serum Albumin Drugs 0.000 description 1
108091003117 Bovine Serum Albumin Proteins 0.000 description 1
CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 1
229950009494 Bropirimine Drugs 0.000 description 1
229950002361 Budotitane Drugs 0.000 description 1
BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
102100005826 CD19 Human genes 0.000 description 1
101700087100 CD19 Proteins 0.000 description 1
101700017647 CD33 Proteins 0.000 description 1
102100016493 CD33 Human genes 0.000 description 1
102100019453 CD7 Human genes 0.000 description 1
101700063101 CD7 Proteins 0.000 description 1
102100008191 CD8A Human genes 0.000 description 1
101700054655 CD8A Proteins 0.000 description 1
229950007258 CRISNATOL Drugs 0.000 description 1
LUEYTMPPCOCKBX-KWYHTCOPSA-N CURACIN-A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
241000282465 Canis Species 0.000 description 1
229960004117 Capecitabine Drugs 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229950007509 Carzelesin Drugs 0.000 description 1
102000005403 Casein Kinases Human genes 0.000 description 1
108010031425 Casein Kinases Proteins 0.000 description 1
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
108050004290 Cecropins Proteins 0.000 description 1
210000000170 Cell Membrane Anatomy 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000252505 Characidae Species 0.000 description 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N Chloramine-T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
229960005091 Chloramphenicol Drugs 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
210000004252 Chorionic Villi Anatomy 0.000 description 1
229950000634 Cicaprost Drugs 0.000 description 1
241000207199 Citrus Species 0.000 description 1
SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
229960003608 Clomifene Drugs 0.000 description 1
229940107775 Clomiphene Drugs 0.000 description 1
229920002676 Complementary DNA Polymers 0.000 description 1
GLESHRYLRAOJPS-DHCFDGJBSA-N Conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
241000218691 Cupressaceae Species 0.000 description 1
NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N Cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
TYVRUMCYJWCOOO-TVEJMLEISA-N Cypemycin Chemical compound C1S\C=C/NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(=C\C)/NC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(\NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)N(C)C)=C/C)=C/C)=C/C)C(C)C)CC1=CC=CC=C1 TYVRUMCYJWCOOO-TVEJMLEISA-N 0.000 description 1
229960000684 Cytarabine Drugs 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
NKLCNNUWBJBICK-UHFFFAOYSA-N Dess–Martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
229960000605 Dexrazoxane Drugs 0.000 description 1
229950005878 Dexverapamil Drugs 0.000 description 1
KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
238000005698 Diels-Alder reaction Methods 0.000 description 1
RXKJFZQQPQGTFL-UHFFFAOYSA-N Dihydroxyacetone Chemical group OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical group CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 description 1
AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
229950011461 EDELFOSINE Drugs 0.000 description 1
229950010033 Ebselen Drugs 0.000 description 1
DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
229950005678 Ecomustine Drugs 0.000 description 1
MHFRGQHAERHWKZ-UHFFFAOYSA-N Edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
108010070635 Edrecolomab Proteins 0.000 description 1
VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
229940087477 Ellence Drugs 0.000 description 1
229950005450 Emitefur Drugs 0.000 description 1
229950009537 Epristeride Drugs 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229960001842 Estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
229940047887 Etopophos Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 Etoposide Drugs 0.000 description 1
229950011548 FADROZOLE Drugs 0.000 description 1
229950005096 FAZARABINE Drugs 0.000 description 1
102100015545 FCGR2A Human genes 0.000 description 1
102100015543 FCGR2B Human genes 0.000 description 1
102100015542 FCGR3B Human genes 0.000 description 1
101710003435 FCGRT Proteins 0.000 description 1
102100014838 FCGRT Human genes 0.000 description 1
102100008634 FGF2 Human genes 0.000 description 1
101700082364 FGF2 Proteins 0.000 description 1
102100004573 FLT3 Human genes 0.000 description 1
101710009074 FLT3 Proteins 0.000 description 1
229950010404 FOSTRIECIN Drugs 0.000 description 1
CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
206010016256 Fatigue Diseases 0.000 description 1
108010021468 Fc gamma receptor IIA Proteins 0.000 description 1
108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
101700050236 Fcgr4 Proteins 0.000 description 1
229960004177 Filgrastim Drugs 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
229950004217 Forfenimex Drugs 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
102100014519 GPNMB Human genes 0.000 description 1
229950004410 Galocitabine Drugs 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
235000005612 Grewia tenax Nutrition 0.000 description 1
244000041633 Grewia tenax Species 0.000 description 1
XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
241000989913 Gunnera petaloidea Species 0.000 description 1
229940093915 Gynecological Organic acids Drugs 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
210000000777 Hematopoietic System Anatomy 0.000 description 1
206010020243 Hodgkin's disease Diseases 0.000 description 1
201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
MPGWGYQTRSNGDD-UHFFFAOYSA-N Hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
229950006905 ILMOFOSINE Drugs 0.000 description 1
229940099279 Idamycin Drugs 0.000 description 1
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
229950002248 Idoxifene Drugs 0.000 description 1
229950009926 Idramantone Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
108010027440 Immunoconjugates Proteins 0.000 description 1
102000018748 Immunoconjugates Human genes 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N Iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
229950000855 Iroplact Drugs 0.000 description 1
229950010984 Irsogladine Drugs 0.000 description 1
GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
210000001503 Joints Anatomy 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
210000003734 Kidney Anatomy 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ZHTRILQJTPJGNK-FYBAATNNSA-N LEINAMYCIN Chemical compound N([C@@H](C=1SC=C(N=1)\C=C/C=C/C(=O)[C@H](O)/C=C(C)/CC1)C)C(=O)C[C@@]21S(=O)SC(=O)[C@]2(C)O ZHTRILQJTPJGNK-FYBAATNNSA-N 0.000 description 1
229950005634 LOXORIBINE Drugs 0.000 description 1
POCZBHBFCIWCCV-UHFFFAOYSA-N Lamellarin N Chemical compound C1=C(O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(O)C=C3C=CN2C2=C1C(C=C(OC)C(O)=C1)=C1OC2=O POCZBHBFCIWCCV-UHFFFAOYSA-N 0.000 description 1
210000001821 Langerhans Cells Anatomy 0.000 description 1
229920001320 Leader sequence (mRNA) Polymers 0.000 description 1
108010062867 Lenograstim Proteins 0.000 description 1
229920001491 Lentinan Polymers 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
210000000265 Leukocytes Anatomy 0.000 description 1
RBBBWKUBQVARPL-SWQMWMPHSA-N Lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
229950008991 Lobaplatin Drugs 0.000 description 1
229950000909 Lometrexol Drugs 0.000 description 1
YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
229950008745 Losoxantrone Drugs 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
108060001084 Luciferase family Proteins 0.000 description 1
210000004072 Lung Anatomy 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
229910052765 Lutetium Inorganic materials 0.000 description 1
210000003712 Lysosomes Anatomy 0.000 description 1
RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
229950002676 MENOGARIL Drugs 0.000 description 1
102100012644 MIF Human genes 0.000 description 1
108090000028 MMP12 Proteins 0.000 description 1
102100000165 MS4A1 Human genes 0.000 description 1
101710010909 MS4A1 Proteins 0.000 description 1
206010025382 Macrocytosis Diseases 0.000 description 1
229940041033 Macrolides Drugs 0.000 description 1
102000001544 Maspin Human genes 0.000 description 1
241001441512 Maytenus serrata Species 0.000 description 1
LWYJUZBXGAFFLP-OCNCTQISSA-N Menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
102000014171 Milk Proteins Human genes 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
229950008541 Mirimostim Drugs 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N Mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 Mitomycin Drugs 0.000 description 1
229950001745 Mitonafide Drugs 0.000 description 1
229960001156 Mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
229950008012 Mofarotene Drugs 0.000 description 1
VAZLWPAHMORDGR-UHFFFAOYSA-L Motexafin gadolinium Chemical compound C1=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=C1[N]1=CC3=[N]4[Gd]11(N56)(OC(=O)C)(OC(=O)C)[N]2=CC(C(C)=C2CCCO)=[N]1C2=CC6=C(CC)C(CC)=C5C=C4C(CCCO)=C3C VAZLWPAHMORDGR-UHFFFAOYSA-L 0.000 description 1
241001502127 Mullus barbatus Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
OWIUPIRUAQMTTK-UHFFFAOYSA-M N-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical compound N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
102100007544 NCAM1 Human genes 0.000 description 1
101700077124 NCAM1 Proteins 0.000 description 1
210000004693 NK cell Anatomy 0.000 description 1
102100020079 NPM1 Human genes 0.000 description 1
101710026364 NPM1 Proteins 0.000 description 1
229960002333 Nafarelin Drugs 0.000 description 1
108010021717 Nafarelin Proteins 0.000 description 1
JZGDNMXSOCDEFQ-UHFFFAOYSA-N Napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
229950010676 Nartograstim Drugs 0.000 description 1
GYAVMUDJCHAASE-UHFFFAOYSA-M Nedaplatin Chemical compound [H][N]([H])([H])[Pt]1([N]([H])([H])[H])OCC(=O)O1 GYAVMUDJCHAASE-UHFFFAOYSA-M 0.000 description 1
229950007221 Nedaplatin Drugs 0.000 description 1
229950010159 Nemorubicin Drugs 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
210000004940 Nucleus Anatomy 0.000 description 1
101710003000 ORF1/ORF2 Proteins 0.000 description 1
229950007318 OZOGAMICIN Drugs 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
229960002700 Octreotide Drugs 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
229950011093 Onapristone Drugs 0.000 description 1
FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 1
229960005343 Ondansetron Drugs 0.000 description 1
229950008017 Ormaplatin Drugs 0.000 description 1
208000002865 Osteopetrosis Diseases 0.000 description 1
206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
229950000039 PELDESINE Drugs 0.000 description 1
102100012884 PF4 Human genes 0.000 description 1
101710014074 PF4 Proteins 0.000 description 1
102100012673 PNP Human genes 0.000 description 1
VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
ZFYKZAKRJRNXGF-XRZRNGJYSA-N Palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
RDIMTXDFGHNINN-IKGGRYGDSA-N Panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
RDIMTXDFGHNINN-BRWVUGGUSA-N Panaxytriol Natural products CCCCCCC[C@@H](O)[C@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-BRWVUGGUSA-N 0.000 description 1
229950003440 Panomifene Drugs 0.000 description 1
229940055729 Papain Drugs 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
DOHVAKFYAHLCJP-UHFFFAOYSA-N Peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
229960002340 Pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
229950009351 Perfosfamide Drugs 0.000 description 1
OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
229950000688 Phenothiazine Drugs 0.000 description 1
210000002826 Placenta Anatomy 0.000 description 1
229960003171 Plicamycin Drugs 0.000 description 1
YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
241001272996 Polyphylla fullo Species 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
229950004406 Porfiromycin Drugs 0.000 description 1
QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
108060007057 RIPPLY Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
108060007040 Rilpl Proteins 0.000 description 1
QXKJWHWUDVQATH-UHFFFAOYSA-N Rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
229950005230 Rogletimide Drugs 0.000 description 1
HNMATTJJEPZZMM-BPKVFSPJSA-N S-[(2R,3S,4S,6S)-6-[[(2R,3S,4S,5R,6R)-5-[(2S,4S,5S)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2S,5Z,9R,13E)-13-[2-[[4-[(2E)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
229950008902 SAFINGOL Drugs 0.000 description 1
108010005173 SERPIN-B5 Proteins 0.000 description 1
230000036141 SERUM STABILITY Effects 0.000 description 1
OTKJDMGTUTTYMP-ROUUACIJSA-N Safingol Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ROUUACIJSA-N 0.000 description 1
210000003296 Saliva Anatomy 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
210000002966 Serum Anatomy 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
230000037165 Serum Concentration Effects 0.000 description 1
108010070144 Single-Chain Antibodies Proteins 0.000 description 1
102000005632 Single-Chain Antibodies Human genes 0.000 description 1
229940083542 Sodium Drugs 0.000 description 1
229940091252 Sodium supplements Drugs 0.000 description 1
229950004225 Sonermin Drugs 0.000 description 1
229950004796 Sparfosic Acid Drugs 0.000 description 1
YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
SFVFIFLLYFPGHH-UHFFFAOYSA-M Stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical group NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
229960001278 Teniposide Drugs 0.000 description 1
229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N Thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
229920000401 Three prime untranslated region Polymers 0.000 description 1
229950002376 Tirapazamine Drugs 0.000 description 1
QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108091005908 Type I transmembrane proteins Proteins 0.000 description 1
210000002700 Urine Anatomy 0.000 description 1
240000004652 Vaccinium ovalifolium Species 0.000 description 1
BNJNAEJASPUJTO-DUOHOMBCSA-N Vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 1
229950001694 Vadastuximab talirine Drugs 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000863480 Vinca Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
208000006110 Wiskott-Aldrich Syndrome Diseases 0.000 description 1
102000001392 Wiskott-Aldrich Syndrome Protein Human genes 0.000 description 1
108010093528 Wiskott-Aldrich Syndrome Protein Proteins 0.000 description 1
201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
229950003017 Zeniplatin Drugs 0.000 description 1
ZMQRJWIYMXZORG-DSWNLJKISA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2R)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-DSWNLJKISA-N 0.000 description 1
ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2R,3S,4R,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
YJTVZHOYBAOUTO-URBBEOKESA-N [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl hydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
NBLHOLNNKJBEDC-XOGQCRKLSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-5-[[(2S,3R)-1-[2-[4-[4-[4-(diaminomethylideneamino)butylcarbamoyl]-1,3-th Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCCN=C(N)N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C NBLHOLNNKJBEDC-XOGQCRKLSA-N 0.000 description 1
PQNNIEWMPIULRS-SUTYWZMXSA-N [(8E,10E,12E)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
QPWBZVAOCWJTFK-UHFFFAOYSA-L [2-(azanidylmethyl)-3-hydroxy-2-(hydroxymethyl)propyl]azanide;cyclobutane-1,1-dicarboxylate;platinum(4+) Chemical compound [Pt+4].[NH-]CC(C[NH-])(CO)CO.[O-]C(=O)C1(C([O-])=O)CCC1 QPWBZVAOCWJTFK-UHFFFAOYSA-L 0.000 description 1
ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 1
OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
150000001241 acetals Chemical class 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
231100000494 adverse effect Toxicity 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000004931 aggregating Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
108010011559 alanylphenylalanine Proteins 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000002152 alkylating Effects 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960002749 aminolevulinic acid Drugs 0.000 description 1
ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
150000005005 aminopyrimidines Chemical class 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
229960002550 amrubicin Drugs 0.000 description 1
229960001694 anagrelide Drugs 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003042 antagnostic Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
108010070670 antarelix Proteins 0.000 description 1
239000003817 anthracycline antibiotic agent Substances 0.000 description 1
230000002280 anti-androgenic Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000001833 anti-estrogenic Effects 0.000 description 1
230000000843 anti-fungal Effects 0.000 description 1
230000000111 anti-oxidant Effects 0.000 description 1
230000000259 anti-tumor Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940045698 antineoplastic Taxanes Drugs 0.000 description 1
239000003972 antineoplastic antibiotic Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229950011088 asulacrine Drugs 0.000 description 1
108010093161 axinastatin 1 Proteins 0.000 description 1
108010093000 axinastatin 2 Proteins 0.000 description 1
108010092978 axinastatin 3 Proteins 0.000 description 1
OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
229930014667 baccatin III Natural products 0.000 description 1
238000002819 bacterial display Methods 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
230000001588 bifunctional Effects 0.000 description 1
BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
229950008548 bisantrene Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
239000012503 blood component Substances 0.000 description 1
MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
238000009583 bone marrow aspiration Methods 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
229960004649 calcipotriene Drugs 0.000 description 1
229960002882 calcipotriol Drugs 0.000 description 1
LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000004452 carbocyclyl group Chemical group 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
150000001728 carbonyl compounds Chemical class 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
229930016259 castanospermine Natural products 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
229960003230 cetrorelix Drugs 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940099111 chloramine-T Drugs 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
150000004035 chlorins Chemical class 0.000 description 1
125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
238000010367 cloning Methods 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
150000004814 combretastatins Chemical class 0.000 description 1
230000004154 complement system Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
108010006226 cryptophycin Proteins 0.000 description 1
108010090203 cryptophycin 8 Proteins 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
150000001925 cycloalkenes Chemical group 0.000 description 1
125000002993 cycloalkylene group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
FHEPZBIUHGLJMP-UHFFFAOYSA-N cyclohexene Chemical group [CH]1CCCC=C1 FHEPZBIUHGLJMP-UHFFFAOYSA-N 0.000 description 1
QKJSVPBYHKEILK-UHFFFAOYSA-N cyclohexene Chemical group C1CCC=[C]C1 QKJSVPBYHKEILK-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
DABYZUWMLUGAGP-UHFFFAOYSA-N cyclopentene Chemical group [CH]1CC=CC1 DABYZUWMLUGAGP-UHFFFAOYSA-N 0.000 description 1
NRADQUVNXZVPHN-UHFFFAOYSA-N cyclopentene Chemical group C1C[C]=CC1 NRADQUVNXZVPHN-UHFFFAOYSA-N 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
108010041566 cypemycin Proteins 0.000 description 1
229950006614 cytarabine ocfosfate Drugs 0.000 description 1
230000001461 cytolytic Effects 0.000 description 1
230000001086 cytosolic Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
229960003603 decitabine Drugs 0.000 description 1
230000004059 degradation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229960005408 deslorelin Drugs 0.000 description 1
238000003795 desorption Methods 0.000 description 1
230000001809 detectable Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 1
SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229950002389 diaziquone Drugs 0.000 description 1
125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
230000029087 digestion Effects 0.000 description 1
230000003467 diminishing Effects 0.000 description 1
229940042396 direct acting antivirals Thiosemicarbazones Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229960000735 docosanol Drugs 0.000 description 1
229960003413 dolasetron Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
229950005454 doxifluridine Drugs 0.000 description 1
229960004242 dronabinol Drugs 0.000 description 1
238000009510 drug design Methods 0.000 description 1
101700056562 ecfA1 Proteins 0.000 description 1
229960001776 edrecolomab Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
229960002759 eflornithine Drugs 0.000 description 1
238000007336 electrophilic substitution reaction Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002255 enzymatic Effects 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
230000001586 eradicative Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
HWMJAPURZLIYQA-JPFZJSEDSA-L ethanolate;(Z)-3-oxo-1-phenylbut-1-en-1-olate;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)\C=C(/[O-])C1=CC=CC=C1.CC(=O)\C=C(/[O-])C1=CC=CC=C1 HWMJAPURZLIYQA-JPFZJSEDSA-L 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
229960000752 etoposide phosphate Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
229950003662 fenretinide Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
230000004992 fission Effects 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
125000004407 fluoroaryl group Chemical group 0.000 description 1
229960004421 formestane Drugs 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
229960004783 fotemustine Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
229940044658 gallium nitrate Drugs 0.000 description 1
210000004475 gamma-delta T lymphocyte Anatomy 0.000 description 1
229960003794 ganirelix Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000003899 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine zwitterion Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000003106 haloaryl group Chemical group 0.000 description 1
125000005216 haloheteroaryl group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002489 hematologic Effects 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
230000003284 homeostatic Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229940005608 hypericin Drugs 0.000 description 1
229960005236 ibandronic acid Drugs 0.000 description 1
TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
229960003696 ilomastat Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
229960002751 imiquimod Drugs 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved Effects 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
125000004926 indolenyl group Chemical group 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000002687 intercalation Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960003795 iobenguane (123I) Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 1
125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
230000000366 juvenile Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000002372 labelling Methods 0.000 description 1
108010021336 lanreotide Proteins 0.000 description 1
229960002437 lanreotide Drugs 0.000 description 1
229960002618 lenograstim Drugs 0.000 description 1
229940115286 lentinan Drugs 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
230000000670 limiting Effects 0.000 description 1
108010020270 lissoclinamide 7 Proteins 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 1
230000002132 lysosomal Effects 0.000 description 1
230000001868 lysosomic Effects 0.000 description 1
238000002824 mRNA display Methods 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
230000003211 malignant Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000003071 memory T lymphocyte Anatomy 0.000 description 1
101700048002 metN Proteins 0.000 description 1
230000003458 metachromatic Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
229960003248 mifepristone Drugs 0.000 description 1
235000021239 milk protein Nutrition 0.000 description 1
229960003775 miltefosine Drugs 0.000 description 1
229950010913 mitolactol Drugs 0.000 description 1
230000035773 mitosis phase Effects 0.000 description 1
230000000394 mitotic Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960003063 molgramostim Drugs 0.000 description 1
108010032806 molgramostim Proteins 0.000 description 1
230000001002 morphogenetic Effects 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
108010032539 nartograstim Proteins 0.000 description 1
239000005445 natural product Substances 0.000 description 1
229930014626 natural products Natural products 0.000 description 1
CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
229950010733 neridronic acid Drugs 0.000 description 1
230000001264 neutralization Effects 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
150000007855 nitrilimines Chemical group 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
125000006574 non-aromatic ring group Chemical group 0.000 description 1
230000003000 nontoxic Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
108010009099 nucleoside phosphorylase Proteins 0.000 description 1
125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
125000002524 organometallic group Chemical group 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
201000006588 ovary adenocarcinoma Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
125000001820 oxy group Chemical compound [*:1]O[*:2] 0.000 description 1
239000001301 oxygen Chemical group 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
229960003978 pamidronic acid Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001744 pegaspargase Drugs 0.000 description 1
108010001564 pegaspargase Proteins 0.000 description 1
125000001147 pentyl group Chemical compound C(CCCC)* 0.000 description 1
229960001217 perflubron Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000036231 pharmacokinetics Effects 0.000 description 1
125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
108010018625 phenylalanylarginine Proteins 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
229960001221 pirarubicin Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
150000003058 platinum compounds Chemical class 0.000 description 1
108010049948 plitidepsin Proteins 0.000 description 1
229960001237 podophyllotoxin Drugs 0.000 description 1
229930001140 podophyllotoxin Natural products 0.000 description 1
230000001402 polyadenylating Effects 0.000 description 1
108091008117 polyclonal antibodies Proteins 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000002335 preservative Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
230000001681 protective Effects 0.000 description 1
230000036678 protein binding Effects 0.000 description 1
238000002818 protein evolution Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory Effects 0.000 description 1
230000002629 repopulating Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000002702 ribosome display Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960002530 sargramostim Drugs 0.000 description 1
108010038379 sargramostim Proteins 0.000 description 1
150000007659 semicarbazones Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
231100000486 side effect Toxicity 0.000 description 1
230000001743 silencing Effects 0.000 description 1
238000003530 single readout Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
101710044770 sll1951 Proteins 0.000 description 1
229950010372 sobuzoxane Drugs 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
239000000758 substrate Substances 0.000 description 1
OJXASOYYODXRPT-UHFFFAOYSA-N sulfamoylurea Chemical group NC(=O)NS(N)(=O)=O OJXASOYYODXRPT-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000011593 sulfur Chemical group 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
201000009594 systemic scleroderma Diseases 0.000 description 1
229960001674 tegafur Drugs 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
108010062880 thiocoraline Proteins 0.000 description 1
PIZNQHDTOZMVBH-UHFFFAOYSA-N thionylimide Chemical compound N=S=O PIZNQHDTOZMVBH-UHFFFAOYSA-N 0.000 description 1
150000003584 thiosemicarbazones Chemical class 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
229960001479 tosylchloramide sodium Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000014616 translation Effects 0.000 description 1
108091007206 transmembrane glycoprotein Proteins 0.000 description 1
108091005683 transmembrane proteins Proteins 0.000 description 1
102000035402 transmembrane proteins Human genes 0.000 description 1
230000032258 transport Effects 0.000 description 1
ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered Effects 0.000 description 1
PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
210000004881 tumor cells Anatomy 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
108091015697 vadastuximab talirine Proteins 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000004034 viscosity adjusting agent Substances 0.000 description 1
229960001771 vorozole Drugs 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1

Images

JP2021521765A 2018-10-30 2019-10-30 抗－ｃｄ４５抗体及びそのコンジュゲート Pending JP2022512778A (ja)